Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Open-Label Safety Study of Weekly Subcutaneous Pegzilarginase in Arginase 1 Deficiency
2022-003722-45Phase 3Terminated
- Sponsor
- Spyre Therapeutics, Inc.
- Start
- Jan 2023
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pegzilarginase in arginase 1 deficiency (ARG1-D), sponsored by Spyre Therapeutics, Inc. Primary endpoint: Safety assessments. Started Jan 2023; status: terminated.
02
Drugs
pegzilarginase
03
Conditions
arginase 1 deficiency (ARG1-D)
Beyond the preview
Go deeper on 2022-003722-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003722-45.